Cargando…

Pembrolizumab induced remission of recurrent and metastatic sinonasal squamous cell carcinoma after overcoming checkpoint‐inhibitor pneumonitis: A case report and literature review

BACKGROUND: For programmed death‐ligand‐1 (PD‐L1) positive recurrent and metastatic head and neck squamous cell carcinoma (R/M‐HNSCC), KEYNOTE‐048 and KEYNOTE‐040 clinical trials recently approved pembrolizumab monotherapy as first‐line treatment. However, recurrent and metastatic sinonasal squamous...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nair, Deepak Rajendran, Trehan, Ram
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363840/ https://www.ncbi.nlm.nih.gov/pubmed/36601913 http://dx.doi.org/10.1002/cnr2.1778

Ejemplares similares

The Synergistic Effect of Immune Checkpoint Blockade and Radiotherapy in Recurrent/Metastatic Sinonasal Cancer
por: Yazici, Gozde, et al.
Publicado: (2018)

Pembrolizumab-induced pneumonitis
por: Leroy, Vincent, et al.
Publicado: (2017)

Chronic immune checkpoint inhibitor pneumonitis
por: Naidoo, Jarushka, et al.
Publicado: (2020)

Response of Metastatic Chordoma to the Immune Checkpoint Inhibitor Pembrolizumab: A Case Report
por: Wu, Xiaoli, et al.
Publicado: (2020)

Pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma in an Asian population
por: Chen, Wen-Chun, et al.
Publicado: (2017)

Correction: Chronic immune checkpoint inhibitor pneumonitis
Publicado: (2020)

Induced Remission of Metastatic Squamous Cell Carcinoma with an Immune Checkpoint Inhibitor in a Patient with Recessive Dystrophic Epidermolysis Bullosa
por: Khaddour, Karam, et al.
Publicado: (2020)

Pembrolizumab: Interstitial bilateral pneumonitis: case report
Publicado: (2021)

Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer
por: Fujimoto, Daichi, et al.
Publicado: (2023)

Case Report: Prolonged remission of metastatic cisplatin-refractory nasopharyngeal carcinoma with Pembrolizumab
por: Wang, Wei Cen, et al.
Publicado: (2023)

Rate and risk factors of recurrent immune checkpoint inhibitor-related pneumonitis in patients with lung cancer
por: Tao, Haitao, et al.
Publicado: (2022)

Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC
por: Reuss, Joshua E., et al.
Publicado: (2021)

Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis
por: Lin, Xinqing, et al.
Publicado: (2022)

Pembrolizumab: Pneumonitis, pulmonary cavitation and haemoptysis: case report
Publicado: (2020)

Overcoming Resistance to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinomas
por: dos Santos, Lucas V., et al.
Publicado: (2021)

Myocardial Vasculitis Associated With the Immune Checkpoint Inhibitor Pembrolizumab
por: Oishi, Hideo, et al.
Publicado: (2020)

Eosinophilic Fasciitis following Checkpoint Inhibitor Therapy with Pembrolizumab
por: Zampeli, Evangelia, et al.
Publicado: (2021)

Immune checkpoint inhibitor–induced diabetes mellitus with pembrolizumab
por: Zand Irani, Anis, et al.
Publicado: (2022)

Immune checkpoint inhibitor lichenoid eruption due to pembrolizumab
por: McCormick, Benjamin Joseph, et al.
Publicado: (2023)

Treatment of Metastatic Disease with Immune Checkpoint Inhibitors Nivolumab and Pembrolizumab: Effect of Performance Status on Clinical Outcomes
por: Wells, Leah, et al.
Publicado: (2022)

Sustained partial remission of a metastatic NEN using off-label immunotherapy with pembrolizumab
por: Stüven, Anna Kathrin, et al.
Publicado: (2019)

Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated pneumonitis
por: Wang, Hanping, et al.
Publicado: (2019)

Cellular analysis of bronchoalveolar lavage fluid to narrow differential diagnosis of checkpoint inhibitor-related pneumonitis in metastatic melanoma
por: Strippoli, Sabino, et al.
Publicado: (2020)

Pembrolizumab-related pneumonitis in a patient with COVID-19 infection
por: Ponnalagu, Venkataganesan, et al.
Publicado: (2022)

A Case of Long-Term Survival after Checkpoint Inhibitor Pneumonitis in a Patient with Squamous Cell Lung Cancer
por: Ashinuma, Hironori, et al.
Publicado: (2019)

Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report
por: Li, Hong, et al.
Publicado: (2017)

HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis
por: Correale, Pierpaolo, et al.
Publicado: (2020)

Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy
por: Serzan, Michael T, et al.
Publicado: (2020)

Long-term outcomes in patients with immune checkpoint inhibitor induced pneumonitis
por: Davis Puente, Andrea, et al.
Publicado: (2023)

Risk factors and immunomodulators use in steroid-refractory checkpoint inhibitor pneumonitis
por: Li, Yanlin, et al.
Publicado: (2023)

Identification and prediction of immune checkpoint inhibitors-related pneumonitis by machine learning
por: Gong, Li, et al.
Publicado: (2023)

Immune checkpoint inhibitors in advanced and recurrent/metastatic cervical cancer
por: Han, Xiling, et al.
Publicado: (2022)

Immunotherapy-related pneumonitis and bacterial pneumonia after the successful treatment of metastatic malignant melanoma with pembrolizumab: A case report
por: Ma, Qin, et al.
Publicado: (2021)

Long-term complete remission after severe pembrolizumab-induced immune-related encephalitis in metastatic lung adeno-squamous carcinoma: A case report
por: Quirynen, Rémy, et al.
Publicado: (2023)

Delayed immune-mediated hepatitis after three cycles of pembrolizumab for the treatment of sinonasal melanoma
por: Kang, S, et al.
Publicado: (2023)

SAT-661 The Lesser Evil: Pembrolizumab Induced Remission of Metastatic Melanoma with Autoimmune Diabetes, Hypothyroidism, and Colitis
por: Harris, Asaf, et al.
Publicado: (2020)

Remission of a Perimyocardial Melanoma Metastasis With Pembrolizumab Treatment
por: Larsen, Frederik Uttenthal, et al.
Publicado: (2019)

Health-Related Quality of Life of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Treated with Pembrolizumab in KEYNOTE-629
por: Hughes, Brett G. M., et al.
Publicado: (2021)

Cost-Effectiveness of Pembrolizumab Regimens for the First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in Argentina
por: Wurcel, Victoria, et al.
Publicado: (2021)

Combination of Pembrolizumab and Stereotactic Body Radiation Therapy in Recurrent Metastatic Penile Squamous Cell Carcinoma: A Case Study
por: Kaakour, Dalia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_31e1ucv4b1qoed0aqti2fho3ir